News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
9,199 Results
Type
Article (1537)
Company Profile (5)
Press Release (7657)
Section
Business (3633)
Career Advice (10)
Deals (516)
Drug Delivery (5)
Drug Development (1711)
Employer Resources (5)
FDA (303)
Job Trends (302)
News (6074)
Policy (558)
Tag
2027 BioCapital Standard (1)
Academia (22)
Accelerated approval (3)
ADA (1)
Adcomms (5)
Allergies (2)
Alliances (1028)
ALS (2)
Alzheimer's disease (18)
Antibody-drug conjugate (ADC) (18)
Approvals (284)
Artificial intelligence (13)
ASCO (3)
Autoimmune disease (15)
Bankruptcy (5)
Best Places to Work (154)
BIOSECURE Act (1)
Biotechnology (2)
Breast cancer (4)
Cancer (115)
Cardiovascular disease (16)
Career advice (12)
CAR-T (1)
CDC (11)
Cell therapy (9)
Clinical research (1445)
Collaboration (58)
Company closure (2)
Compensation (5)
Complete response letters (4)
COVID-19 (120)
CRISPR (3)
C-suite (50)
Cystic fibrosis (1)
Data (81)
Denatured (3)
Depression (2)
Dermatology (2)
Diabetes (1)
Diagnostics (28)
Digital health (1)
Diversity, equity & inclusion (2)
Drug discovery (6)
Drug pricing (14)
Duchenne muscular dystrophy (4)
Earnings (1091)
Editorial (9)
Employer branding (2)
Employer resources (5)
Events (773)
Executive appointments (38)
FDA (332)
Frontotemporal dementia (2)
Funding (28)
Gene editing (5)
Generative AI (1)
Gene therapy (11)
GLP-1 (19)
Government (94)
Guidances (2)
Healthcare (191)
Hematology (1)
HIV (18)
Huntington's disease (1)
Immunology and inflammation (32)
Immuno-oncology (5)
Indications (5)
Infectious disease (189)
Inflammatory bowel disease (2)
Inflation Reduction Act (2)
Influenza (4)
Intellectual property (4)
IPO (131)
IRA (3)
Job creations (148)
Job search strategy (9)
JPM (7)
Labor market (4)
Layoffs (29)
Leadership (3)
Legal (153)
Liver cancer (2)
Longevity (1)
Lung cancer (16)
Lymphoma (3)
Machine learning (1)
Management (2)
Manufacturing (19)
MASH (8)
Medical device (16)
Medtech (17)
Mergers & acquisitions (391)
Metabolic disorders (27)
mRNA (17)
Multiple sclerosis (1)
Neurodegenerative disease (18)
Neuropsychiatric disorders (4)
Neuroscience (43)
Neurotech (1)
NextGen: Class of 2026 (77)
Non-profit (31)
Now hiring (1)
Obesity (17)
Opinion (13)
Ovarian cancer (9)
Pain (1)
Pancreatic cancer (13)
Parkinson's disease (1)
Partnered (1)
Patents (12)
Patient recruitment (6)
People (1398)
Pharmaceutical (2)
Pharmacy benefit managers (1)
Phase 1 (366)
Phase 2 (580)
Phase 3 (589)
Pipeline (163)
Policy (29)
Postmarket research (98)
Preclinical (110)
Prostate cancer (6)
Psychedelics (2)
Radiopharmaceuticals (4)
Rare diseases (32)
Real estate (76)
Recruiting (1)
Regulatory (439)
Reports (2)
Research institute (29)
Resumes & cover letters (1)
RNA editing (2)
RSV (32)
Schizophrenia (1)
Series A (5)
Series B (2)
Sickle cell disease (4)
Special edition (5)
Spinal muscular atrophy (11)
Sponsored (1)
Startups (109)
Stomach cancer (5)
Supply chain (2)
Tariffs (6)
The Weekly (13)
Vaccines (121)
Venture capital (13)
Weight loss (11)
Date
Today (2)
Last 7 days (6)
Last 30 days (33)
Last 365 days (471)
2026 (233)
2025 (462)
2024 (497)
2023 (532)
2022 (727)
2021 (607)
2020 (516)
2019 (409)
2018 (331)
2017 (401)
2016 (429)
2015 (658)
2014 (462)
2013 (384)
2012 (337)
2011 (394)
2010 (385)
Location
Africa (36)
Arizona (1)
Asia (590)
Australia (172)
California (136)
Canada (49)
China (29)
Colorado (1)
Connecticut (2)
Delaware (2)
Europe (3219)
Florida (15)
Georgia (8)
Illinois (33)
Indiana (3)
Japan (3)
Maryland (8)
Massachusetts (143)
Nevada (1)
New Hampshire (5)
New Jersey (48)
New York (16)
North Carolina (10)
Northern California (62)
Oklahoma (1)
Pennsylvania (35)
Puerto Rico (1)
South America (22)
Southern California (53)
Texas (51)
United States (483)
Utah (4)
Virginia (2)
Washington D.C. (3)
Washington State (7)
Wisconsin (1)
9,199 Results for "gsk".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
GSK, Spero’s oral antibiotic wins first FDA nod for complicated UTI
After being rejected in June 2022, GSK paid Spero Therapeutics $66 million for an exclusive worldwide license to develop and commercialize the drug. It’s the second oral antibiotic GSK has brought to market since the beginning of last year.
June 18, 2026
·
2 min read
·
Tristan Manalac
Earnings
GSK’s Shingrix strategy shift drives sales beat even as vaccines slow
While sales for most of GSK’s shots slumped as vaccine skepticism continues to climb in the U.S., Shingrix jumped 20% to almost $1.4 billion in the first quarter, emerging as the pharma’s top-selling product.
April 29, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year
Nuvalent Bio is GSK’s third big-ticket purchase this year, after the pharma dropped $2.2 billion in January for RAPT Therapeutics and $950 million in February for 35Pharma.
June 9, 2026
·
2 min read
·
Tristan Manalac
Podcast
Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence
Eli Lilly and obesity rival Novo Nordisk stole the show at the American Diabetes Association conference, though plenty of other companies also had data to show for their own weight loss assets; GSK strikes the biggest traditional pharma buyout of 2026; and FDA initiatives still lack clarity.
June 10, 2026
·
2 min read
·
Jef Akst
Weight loss
GSK goes beyond weight-loss with $1B buyout of Chinese siRNA specialist
With Siran Biotechnology under its fold, GSK will have access to a long-acting siRNA therapy that could induce weight loss while preserving lean mass, in addition to addressing other weight-related comorbidities.
May 7, 2026
·
2 min read
·
Tristan Manalac
Regulatory
GSK again pulls application for leucovorin, touted by FDA as potential autism treatment
GSK discontinued Wellcovorin in 1999, but the FDA in September last year asked the pharma to refile an application, pointing to its potential to treat cerebral folate deficiency with “autistic features.”
April 10, 2026
·
2 min read
·
Tristan Manalac
Earnings
GSK Says No to GLP-1s, Prioritizes ‘Downstream Effects’ of Obesity
Instead of joining the increasingly crowded GLP-1 arena, GSK will focus its efforts downstream of obesity—a push currently anchored by its Phase III-ready FGF21 analog efimosfermin alfa for liver fibrosis.
February 4, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Deerfield Management Announces Portfolio Company Nuvalent, Inc. to be Acquired by GSK
June 11, 2026
·
4 min read
Rare diseases
GSK Hands RNA Editor Back to Wave After Underwhelming Early AATD Data
While GSK did not provide a specific reason for returning Wave Life Sciences’ WVE-006, the decision comes after the asset in September 2025 came below analyst expectations in a Phase Ib/IIa AATD study.
February 2, 2026
·
2 min read
·
Tristan Manalac
Infectious disease
GSK, Ionis Achieve Functional Cure in Hepatitis B Studies, Clearing Path for FDA Run
Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.
January 7, 2026
·
2 min read
·
Tristan Manalac
1 of 920
Next
